Search
Biogen Inc
BIIBAdd to Watchlist
211.190USD
-1.310-0.62%
Market hours 09/09, 15:46（ET）
31.19BMarket Cap
22.59P/E TTM
Revenue Breakdown
Currency: USDUpdated: Fri, Aug 28
Currency: USDUpdated: Fri, Aug 28
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Spinal Muscular Atrophy-SPINRAZA
601.70M
21.99%
MS product revenues-TYSABRI
450.80M
16.48%
MS product revenues-Fumarate
287.40M
10.50%
MS product revenues-Interferon
225.10M
8.23%
Biosimilar product revenues-BENEPALI
106.80M
3.90%
Other
1.06B
38.90%
By RegionUSD
Name
Revenue
Proportion
United States
3.91B
0.00%
Rest of world
801.90M
29.31%
United states-Revenues from anti-CD20 therapeutic
513.50M
18.77%
Rest of World-Other revenues
242.40M
8.86%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Spinal Muscular Atrophy-SPINRAZA
601.70M
21.99%
MS product revenues-TYSABRI
450.80M
16.48%
MS product revenues-Fumarate
287.40M
10.50%
MS product revenues-Interferon
225.10M
8.23%
Biosimilar product revenues-BENEPALI
106.80M
3.90%
Other
1.06B
38.90%